Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.

ASX Releases

Results of 2017 Annual General Meeting Incorporating Proxy Results

30 November 2017

  Adelaide, Australia, 28 November 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, confirms in accordance with Listing Rule 3.13.2, the results for each of the resolutions put to the Annual General Meeting held at 2:00 pm on Tuesday 28 November 2017 was as follows: Ordinary Business Resolution 2 – Re-election of Meera Verma as a Director The instructions given to validly appointed proxies in respect of the Resolution were as follows: For Against Open Proxies Abstain 40,544,394 3,199,247 677,280 92,135 Result: Resolution Carried by a show of hands Resolution 3 – Adoption of Remuneration Report The instructions given to validly appointed proxies in respect of the Resolution were as follows: For Against Open proxies Abstain 22,758,167 2,227,811 704,280 144,979 Result: Resolution Carried by a show of hands Resolution 4 – Ratification of Prior Share Issue Placement for Purpose of Listing Rule 7.4: Reset o


Read more...

Update following major USA tradeshow

17 November 2017

Adelaide, Australia, 17 November 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced an expanded presence at the American Academy of Ophthalmology (AAO) in New Orleans held between 11-14 November Ellex successfully demonstrated its technology and product portfolio at the AAO which is the USA’s preeminent ophthalmic convention, attracting more than 13,000 ophthalmologists from across the globe. “Not only is the AAO annual meeting the major event on the global ophthalmic industry calendar, but has only traditionally resulted in new sales orders for our laser and ultrasound products. On average, between 9-12% of Ellex’s annual US laser and ultrasound sales are made at the Ellex exhibit during the AAO. The orders received this year exceed orders received last year. For Ellex iTrack, because of the nature of the sale process sales are not made at the exhibit, but it is fair to say that sales lead g


Read more...

Equity capital for Ellex iTrackTM expansion

3 November 2017

Highlights Commitments received from US and Australian institutional investors in a private placement raising approximately A$23 million at an issue price of A$1.05 per share Share Purchase Plan, capped at A$5 million, to be offered to existing shareholders at the same issue price Ellex is now well placed to take advantage of the significant industry-wide transition away from pharmaceuticals towards new treatment options for glaucoma including MIGS* devices Proceeds will be primarily used to accelerate sales of the Ellex iTrackTM into the MIGS device market which is expected to grow from US$240m today to US$1.4bn over the next 5 years.PlacementAdelaide, Australia, 3 November, 2017 – Ellex Medical Lasers Limited (ASX: ELX) (‘Ellex’ or ‘Company’) today announces that it has received commitments from US and Australian institutional and sophisticated investors to subscribe for 22.1 million fully paid ordinary shares in Ellex (‘Shares’) at A$1.05 per Share to raise approximately A$23.2 mill


Read more...

Annual Report 2016

View Share Price

Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.

Corporate Governance

Share Trading Policy